[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
April 12, 2006

Public Health Strategies for Pandemic InfluenzaEthics and the Law

Author Affiliations
 

Author Affiliation: Center for Law and the Public's Health, Georgetown University, Washington, DC, and Johns Hopkins University, Baltimore, Md.

JAMA. 2006;295(14):1700-1704. doi:10.1001/jama.295.14.1700

Highly pathogenic influenza A(H5N1) is endemic in avian populations in Southeast Asia, with serious outbreaks now in Africa, Europe, and the Middle East.1 Human cases, although rare, continue to increase, with high reported case-fatality rates. Industrialized countries place great emphasis on scientific solutions. The White House strategic plan and congressional appropriation both devote more than 90% of pandemic influenza spending to vaccines and antiviral medications.2 Yet, medical countermeasures, discussed in a previous JAMA Commentary, will not impede pandemic spread: experimental H5N1 vaccines may not be effective against a novel human subtype, neuraminidase inhibitors may become resistant, and medical countermeasures will be extremely scarce.3 This Commentary focuses on traditional public health interventions, drawing lessons from past influenza pandemics and the outbreaks of severe acute respiratory syndrome (SARS)4 (Table).

First Page Preview View Large
First page PDF preview
First page PDF preview
×